RxDoctor Payments Data

Amatu Rabbi, MD

Endocrinology, Diabetes & Metabolism · Atlanta, GANPI 1619079878

Payments from drug & device makers

$6,232in general payments, 2019–2025

Across 368 payments — averaging $16.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$910
  • Amgen$757
  • Pfizer$635
  • AbbVie$592
  • AstraZeneca$479
  • Lilly USA, LLC$468
  • plus $2K from 33 others

What the payments were for

  • Food & beverage$6,13898%
  • Education$811%
  • Entertainment$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,232 in reported general payments places this provider in the 60th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.

See all endocrinology, diabetes & metabolism providers in Georgia

Medicare billing

Part B allowed, 2024
$299,314
Medicare patients
421
Services billed
3,934

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin244$314,248
MounjaroTirzepatide178$257,661
EliquisApixaban121$122,113
OzempicSemaglutide73$118,555
RybelsusSemaglutide44$78,639
XareltoRivaroxaban23$38,330
Breo ElliptaFluticasone/Vilanterol33$25,784
FarxigaDapagliflozin Propanediol20$21,617
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/718$19,617
JanuviaSitagliptin Phosphate14$17,242
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$17,195
SynthroidLevothyroxine Sodium132$11,111
SymbicortBudesonide/Formoterol Fumarate27$10,896
EntrestoSacubitril/Valsartan11$8,392
Rosuvastatin Calcium628$6,690

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$116$314,248244 claims
Lilly USA, LLCMounjaro$468$257,661178 claims
Novo NordiskOzempic, Rybelsus$910$197,194117 claims
PfizerEliquis$635$122,113121 claims
GSKBreo Ellipta, Trelegy Ellipta, Arnuity Ellipta$238$48,22479 claims
Johnson & JohnsonXarelto$63$38,33023 claims
AstraZenecaFarxiga, Symbicort$479$32,51347 claims
AbbVieSynthroid$592$11,111132 claims
NovartisEntresto$325$8,39211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.

Other endocrinology, diabetes & metabolism in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →